About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05744297

NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven b...

Lead sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Julien Seiller, MD

CONTACT

478 617 757 jseiller@chsjsl.fr

Sponsors

Lead Sponsor

Centre Hospitalier Saint Joseph Saint Luc de Lyon

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score \> 8
•Aged \> 18

Exclusion Criteria

•Gout treatment already started
•Inflammatory Arthritis other than Gout Arthritis
•Pregnant or breast feeding women
•Patient protected by law

Related studies

RECRUITINGPhase 4

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

NCT07346079 · Gout Arthritis, Gout Flare, and more

Enrolling By InvitationNA

Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity

NCT07310849 · Type2Diabetes, Hypertension, and more

Not Yet RecruitingPhase 4

HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness

NCT07369622 · Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, and more

COMPLETEDPhase 3

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

NCT05983445 · Acute Gout Arthritis

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

NCT06270225 · Gout Arthritis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 12, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment10

Start dateApr 2023

Last updatedMay 12, 2023

Condition

Locations shown

Centre Hospitalier Saint Joseph Saint Luc

Lyon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 12, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions